Company Filing History:
5 out of 14 
1 out of 5 
1 out of 1 Years Active: 2022-2025
Title: Innovations of Inventor Lina Qian
Introduction
Lina Qian is a prominent inventor based in Hubei, China. She has made significant contributions to the field of pharmaceutical development, particularly in the area of triazole compounds and their applications. With a total of three patents to her name, her work focuses on addressing LPAR1-related diseases and disorders.
Latest Patents
Lina Qian's latest patents include innovative compounds that exhibit promising therapeutic potential. One of her notable patents is for triazole compounds and their preparation methods. These compounds demonstrate good LPAR1 antagonistic activity and selectivity, low toxicity, and excellent metabolic stability. They can be utilized for preventing or treating LPAR1-related diseases, with some compounds showing an IC50 value below 300 nM, and even as low as 50 nM. Additionally, the range of CC50 values for these triazole compounds can exceed 200 μM, indicating their safety profile. Another significant patent involves lysophosphatidic acid receptor antagonists, which also show high LPAR1 antagonist activity, low toxicity, and good metabolic stability in humans, mice, and rats. The IC50 values for these compounds may also be as low as 300 nM or below, with CC50 values potentially reaching 200 μM or above.
Career Highlights
Throughout her career, Lina Qian has worked with various companies, including Wuhan LL Science and Technology Development Co., Ltd. and Wuhan QR Pharmaceuticals Co., Ltd. Her expertise in pharmaceutical research has positioned her as a valuable asset in the industry.
Collaborations
Lina Qian has collaborated with notable professionals in her field, including Yongkai Chen and Chaodong Wang. These partnerships have contributed to her innovative research and development efforts.
Conclusion
Lina Qian's contributions to the field of pharmaceutical innovation are noteworthy. Her patents reflect her commitment to advancing medical science and improving treatment options for LPAR1-related diseases. Her work continues to inspire future innovations in the industry.